ReviewThe Journal of antimicrobial chemotherapy2021
Consumption of quinolones in the community, European Union/European Economic Area, 1997-2017.
Review in The Journal of antimicrobial chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Redefining Fluoroquinolone Antibiotics: Design and Synthesis of Degradable Fluoroquinolones to Reduce Environmental Persistence.ChemSusChem · 2026Article
- Fluoroquinolone-Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real-World Data From FAERS (2011-2024).Pharmacology research & perspectives · 2026Article
- Deciphering the Intricate Interplay in the Framework of Antibiotic-Drug Interactions: A Narrative Review.Antibiotics (Basel, Switzerland) · 2024Review
- A Decade of Antimicrobial Resistance in Human and AnimalAntibiotics (Basel, Switzerland) · 2024Review
- Metal Oxide Nanostructures (MONs) as Photocatalysts for Ciprofloxacin Degradation.International journal of molecular sciences · 2023Review
- Effects of Single and Combined Ciprofloxacin and Lead Treatments on Zebrafish Behavior, Oxidative Stress, and Elements Content.International journal of molecular sciences · 2023Article
- Antimicrobial Consumption from 2017 to 2021 in East Trinidad and Tobago: A Study in the English-Speaking Caribbean.Antibiotics (Basel, Switzerland) · 2023Article
- Efficient Removal of Methylene Blue and Ciprofloxacin from Aqueous Solution Using Flower-like, Nanostructured ZnO Coating under UV Irradiation.Nanomaterials (Basel, Switzerland) · 2022Article
- Consumption of Antibacterials for Systemic Use in Slovakia: A National Study and the Quality Indicators for Outpatient Antibiotic Use.Antibiotics (Basel, Switzerland) · 2021Article
- Impact of changing reimbursement criteria on the use of fluoroquinolones in Belgium.The Journal of antimicrobial chemotherapy · 2021Article
- Quality appraisal of antibiotic consumption in the community, European Union/European Economic Area, 2009 and 2017.The Journal of antimicrobial chemotherapy · 2021Article
- Consumption of antibiotics in the community, European Union/European Economic Area, 1997-2017.The Journal of antimicrobial chemotherapy · 2021Review
- Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997-2017.The Journal of antimicrobial chemotherapy · 2021Review
- Consumption of antibiotics in the community, European Union/European Economic Area, 1997-2017: data collection, management and analysis.The Journal of antimicrobial chemotherapy · 2021Article
- Analysing the trend over time of antibiotic consumption in the community: a tutorial on the detection of common change-points.The Journal of antimicrobial chemotherapy · 2021Article
- Change-points in antibiotic consumption in the community, European Union/European Economic Area, 1997-2017.The Journal of antimicrobial chemotherapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesData on quinolone consumption in the community were collected from 30 EU/European Economic Area (EEA) countries over two decades. This article reviews temporal trends, seasonal variation, presence of change-points and changes in the composition of main subgroups of quinolones.
methodsFor the period 1997-2017, data on consumption of quinolones, i.e. ATC group J01M, in the community and aggregated at the level of the active substance, were collected using the WHO ATC/DDD methodology (ATC/DDD index 2019). Consumption was expressed in DDD per 1000 inhabitants per day and in packages per 1000 inhabitants per day. Quinolone consumption was analysed by subgroups based on pharmacokinetic profile, and presented as trends, seasonal variation, presence of change-points and compositional changes.
resultsIn 2017, quinolone consumption in the community expressed in DDD per 1000 inhabitants per day varied by a factor of 8.2 between countries with the highest (Bulgaria) and the lowest (Norway) consumption. The second-generation quinolones accounted for >50% of quinolone consumption in most countries. Quinolone consumption significantly increased up to 2001, and did not change significantly afterwards. Seasonal variation increased significantly over time. Proportional consumption of third-generation quinolones significantly increased over time relative to that of second-generation quinolones, while proportional consumption of both third- and second-generation quinolones significantly increased relative to that of first-generation quinolones. Levofloxacin and moxifloxacin represented >40% of quinolone consumption in the community in southern EU/EEA countries.
conclusionsQuinolone consumption in the community is no longer increasing in the EU/EEA, but its seasonal variation continues to increase significantly as is the proportion of quinolones to treat respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.